BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  Deals

  Biopharma Investment Activity Continued to Rise in Q2: J.P. Morgan

  A report from J.P. Morgan shows an increase in biopharma activity so far this year and where some improvement can be made.

  July 31, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• 

  Alzheimer’s disease

  New Leqembi Data Illuminate Longer-Term Effects, Tau Reduction

  Eisai presented a plethora of data on the drug at the Alzheimer’s Association International Conference, including a study showing the consequences of pausing treatment.

  July 31, 2024

   · 

  5 min read

   · 

  Kate Goodwin
• Press Releases

  Inari Medical Reports Second Quarter 2024 Financial Results

  July 31, 2024

   · 

  11 min read
• Press Releases

  MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte

  July 31, 2024

   · 

  5 min read
• Press Releases

  Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

  July 31, 2024

   · 

  9 min read
• Press Releases

  MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

  July 31, 2024

   · 

  1 min read
• Press Releases

  New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

  July 31, 2024

   · 

  25 min read
• Press Releases

  Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

  July 31, 2024

   · 

  1 min read
• Press Releases

  DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible

  July 31, 2024

   · 

  16 min read
• Press Releases

  Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary

  July 31, 2024

   · 

  3 min read